Evoked Otoacoustic Emissions as Objective Screeners for Ototoxicity

Brenda L. Lonsbury-Martin; Glen K. Martin

doi:10.1055/s-2001-19111

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000067.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Semin Hear 2001; 22(4): 377-392
DOI: 10.1055/s-2001-19111

Evoked Otoacoustic Emissions as Objective Screeners for Ototoxicity

Brenda L. Lonsbury-Martin, Glen K. Martin

Department of Otolaryngology-Head and Neck Surgery, University of Colorado Health Sciences Center, Denver, Colorado

Further Information

Publication History

Publication Date:
18 December 2001 (online)

Also available at

Abstract
Full Text
References

Buy Article Permissions and Reprints

ABSTRACT

Ototoxicity produces hearing losses that are irreversible. The only certain method of preventing debilitating ototoxicity is to detect it as early as possible in the treatment regimen so that medications can be substituted, doses changed, and/or the mode of administration altered. With increasing survival rates of patients requiring ototoxic medication (e.g., aminoglycosides, cisplatin), early detection of ototoxicity is important for providing effective management options. A protocol including the use of otoacoustic emissions to detect and monitor the impact of ototoxicity will be presented.

KEYWORD

Ototoxicity - aminoglycoside - cisplatin - hearing monitoring

REFERENCES

1 American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA . 1994 (Suppl 12); 36 11-19

PubMed Search in Google Scholar
2 Fausti S A, Henry J A, Helt W J. An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear . 1999; 20 497-505

Crossref PubMed Search in Google Scholar
3 Wright C G, Schaefer S D. Inner ear histopathology in patients treated with cisplatin. Laryngoscope . 1982; 92 1408-1413

PubMed Search in Google Scholar
4 Myers S F, Blakley B W, Schwan S. Is cis-platinum vestibulotoxic?. Otolaryngol Head Neck Surg . 1993; 108 322-328

PubMed Search in Google Scholar
5 Strauss M, Towfighi J, Lord S, Lipton A, Harvey H A, Brown B. Cis-platinum ototoxicity: Clinical experience and temporal bone histopathology. Laryngoscope . 1983; 93 1554-1559

PubMed Search in Google Scholar
6 Priuska E M, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol . 1995; 50 1749-1752

Crossref PubMed Search in Google Scholar
7 Sha S H, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res . 2001; 155 1-8

Crossref PubMed Search in Google Scholar
8 McAlpine A, Johnstone B M. The ototoxic mechanism of cisplatin. Hear Res . 1990; 47 191-204

Crossref PubMed Search in Google Scholar
9 Kemp D T. Stimulated acoustic emissions from within the human auditory system. J Acoust Soc Am . 1978; 64 1386-1391

Crossref PubMed Search in Google Scholar
10 Kemp D T. Evidence of mechanical nonlinearity and frequency selective wave amplification in the cochlea. Arch Otorhinolaryngol . 1979; 224 37-45

PubMed Search in Google Scholar
11 Henley C M. Kanamycin depletes cochlear polyamines in the developing rat. Otolaryngol Head Neck Surg . 1994; 110 103-109

PubMed Search in Google Scholar
12 McPhee J R, Sperling N M, Madell J R, Lucente F E. Early detection of ototoxicity using high frequency distortion product otoacoustic emissions. Abstr Assoc Res Otolaryngol . 1994; 17 49

PubMed Search in Google Scholar
13 Hotz M A, Harris F P, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope . 1994; 14 1130-1134

PubMed Search in Google Scholar
14 Ozturan O, Jerger J, Lew H, Lynch G R. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Auris Nasus Larynx . 1996; 23 147-151

PubMed Search in Google Scholar
15 Zorowka P G, Schmitt H J, Gutjahr P. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy. Int J Pediatr Otorhinolaryngol . 1993; 25 73-80

Crossref PubMed Search in Google Scholar
16 Whitehead M L, Stagner B B, Lonsbury-Martin B L, Martin G K. Measurement of otoacoustic emissions for hearing assessment. IEEE Eng Med Biol . 1994; 13 210-226

PubMed Search in Google Scholar
17 Henley C M, Rybak L P. Ototoxicity in developing mammals. Br Res Rev . 1995; 20 68-90

PubMed Search in Google Scholar
18 Allen G C, Tiu C, Koike K, Ritchey A K, Kurs-Lasky M, Wax M K. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol Head Neck Surg . 1988; 118 584-588

PubMed Search in Google Scholar
19 Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamapoulos G. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol . 2001; 59 47-57

Crossref PubMed Search in Google Scholar
20 Ress B D, Sridhar K S, Balkany T J, Waxman G M, Stagner B B, Lonsbury-Martin B L. Effects of cis-platinum chemotherapy on otoacoustic emissions: development of an objective screening protocol. Otolaryngol Head Neck Surg . 1999; 121 693-701

Crossref PubMed Search in Google Scholar
21 Katbamna B, Homnick D N, Marks J H. Effects of chronic tobramycin treatment on distortion product otoacoustic emissions. Ear Hear . 1999; 20 393-402

PubMed Search in Google Scholar
22 Mulheran M, Degg C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br J Audiol . 1997; 31 5-9

Crossref PubMed Search in Google Scholar
23 Katona G, Revai K, Farkas Z, Czinner A, Pataki L. Distortion-product otoacoustic emission screening in netilmicin-treated newborns. J Audiol Med . 1198; 7 10-14

PubMed Search in Google Scholar
24 Wax T, DiPietro L. Managing Hearing Loss in Later Life. National Information Center on Deafness (NICD) Washington, DC: Gallaudet University; 1991

Search in Google Scholar
25 Lonsbury-Martin B L, Cutler W M, Martin G K. Evidence for the influence of aging on distortion-product otoacoustic emissions in humans. J Acoust Soc Am . 1991; 89 1749-1759

PubMed Search in Google Scholar
26 Stover L, Norton S J. The effects of aging on otoacoustic emissions. J Acoust Soc Am . 1993; 94 2670-2681

PubMed Search in Google Scholar
27 Owens J J, McCoy M J, Lonsbury-Martin B L, Martin G K. Influence of otitis media on evoked otoacoustic emissions in children. Semin Hear . 1992; 13 53-66

PubMed Search in Google Scholar
28 Margolis R H, Trine M B. Influence of middle-ear disease on otoacoustic emissions. In: Robinette MS, Glattke TJ, eds. Otoacoustic Emissions: Clinical Applications New York: Thieme 1997: 130-150

Search in Google Scholar
29 Mencher G T, Novotny G, Mencher L, Gulliver M. Ototoxicity and irradiation: additional etiologies of hearing loss in adults. J Am Acad Audiol . 1995; 6 351-357

PubMed Search in Google Scholar
30 Madasu R, Ruckenstein M J, Leake F, Steere E, Robbins K T. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg . 1997; 123 978-981

PubMed Search in Google Scholar
31 Buhrer C, Weinel P, Sauter S, Reiter A, Riehm H. Acute deafness in a 4-year old girl after a single infusion of cis-platinum. Pediatr Hematol Oncol . 1990; 7 145-148

PubMed Search in Google Scholar
32 Decker T N. General recording considerations and clinical instrument options. In: Robinette MS, Glattke TJ, eds. Otoacoustic Emissions: Clinical Applications New York: Thieme 1997: 307-332

Search in Google Scholar
33 Sutton L A, Lonsbury-Martin B L, Martin G K, Whitehead M L. Sensitivity of distortion-product otoacoustic emissions in humans to tonal over- exposure: time course of recovery and effects of lowering L₂ . Hear Res . 1994; 75 161-174

Crossref PubMed Search in Google Scholar
34 Gorga M P, Stover L, Neely S T, Montoya D. The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements. J Acoust Soc Am . 1996; 100 968-977

PubMed Search in Google Scholar
35 Dorn P A, Piskorski P, Gorga M P, Neely S T, Keefe D H. Predicting audiometric status from distortion product otoacoustic emissions using multivariate analysis. Ear Hear . 1999; 20 149-163

PubMed Search in Google Scholar